Literature DB >> 29748720

Aerobic fitness alters the capacity of mononuclear cells to produce pentraxin 3 following maximal exercise.

Aaron L Slusher1, Tiffany M Zúñiga2, Edmund O Acevedo2.   

Abstract

PURPOSE: Pentraxin 3 (PTX3) is a vital regulator of innate immune function. Although plasma PTX3 concentrations are elevated with aerobic fitness, the cellular functions of PTX3 remain unknown in aerobically trained and untrained subjects.
METHODS: Thirty individuals (aerobically trained = 15 and untrained = 15) participated in a maximal exercise protocol to examine ex vivo PTX3 production from isolated peripheral blood mononuclear cells (PBMCs) exposed to LPS or palmitate. The capacity of PTX3 to stimulate inflammatory cytokine production ex vivo was also examined.
RESULTS: Elevated plasma PTX3 concentrations prior to exercise were positively associated with the percent change (pre to post exercise) in plasma PTX3 concentrations in all subjects, independent of cardiorespiratory fitness (VO2max). In addition, elevated plasma PTX3 concentrations in aerobically trained subjects at rest predicted changes in the LPS- and palmitate-stimulated PTX3 production from isolated PBMCs following acute exercise. In response to PTX3 simulation, the capacity of PBMCs to produce the anti-inflammatory cytokine IL-10 was decreased following acute exercise in all subject (no changes in IL-6, TGF-β1, and TNF-α observed). However, the percent change in IL-6 production was positively associated with VO2max in all subjects, and in aerobically trained subjects only, positively associated with elevated plasma PTX3 concentrations at rest and in response to acute exercise.
CONCLUSION: These results suggest that aerobic training enhances the utilization of plasma PTX3 concentrations to predict the capacity of mononuclear cells to produce PTX3, and potentially, its reciprocal role of PTX3 as an initiator of the innate immune response following maximal exercise.

Entities:  

Keywords:  Aerobic fitness; Cytokines; Inflammation; Lipopolysaccharide; Maximal exercise; Palmitate; Pentraxin 3 (PTX3)

Mesh:

Substances:

Year:  2018        PMID: 29748720     DOI: 10.1007/s00421-018-3882-3

Source DB:  PubMed          Journal:  Eur J Appl Physiol        ISSN: 1439-6319            Impact factor:   3.078


  41 in total

1.  International physical activity questionnaire: 12-country reliability and validity.

Authors:  Cora L Craig; Alison L Marshall; Michael Sjöström; Adrian E Bauman; Michael L Booth; Barbara E Ainsworth; Michael Pratt; Ulf Ekelund; Agneta Yngve; James F Sallis; Pekka Oja
Journal:  Med Sci Sports Exerc       Date:  2003-08       Impact factor: 5.411

2.  Elevated plasma pentraxin 3 levels are associated with development and progression of diabetic retinopathy in Korean patients with type 2 diabetes mellitus.

Authors:  Hyun Seung Yang; Jong Eun Woo; Sung Ju Lee; So Hyun Park; Je Moon Woo
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-08-26       Impact factor: 4.799

3.  TLR4 links innate immunity and fatty acid-induced insulin resistance.

Authors:  Hang Shi; Maia V Kokoeva; Karen Inouye; Iphigenia Tzameli; Huali Yin; Jeffrey S Flier
Journal:  J Clin Invest       Date:  2006-10-19       Impact factor: 14.808

4.  Association of pentraxin 3 with insulin resistance and glucose response following maximal aerobic exercise in obese and normal-mass individuals.

Authors:  Aaron L Slusher; Chun-Jung Huang
Journal:  Can J Physiol Pharmacol       Date:  2016-02-12       Impact factor: 2.273

5.  The impact of obesity on pentraxin 3 and inflammatory milieu to acute aerobic exercise.

Authors:  Aaron L Slusher; J Thomas Mock; Michael Whitehurst; Arun Maharaj; Chun-Jung Huang
Journal:  Metabolism       Date:  2014-10-29       Impact factor: 8.694

6.  Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study.

Authors:  Nancy Swords Jenny; Alice M Arnold; Lewis H Kuller; Russell P Tracy; Bruce M Psaty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-01-22       Impact factor: 8.311

Review 7.  The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling.

Authors:  Barbara Bottazzi; Antonio Inforzato; Massimo Messa; Marialuisa Barbagallo; Elena Magrini; Cecilia Garlanda; Alberto Mantovani
Journal:  J Hepatol       Date:  2016-02-26       Impact factor: 25.083

8.  Defective inflammatory response in interleukin 6-deficient mice.

Authors:  E Fattori; M Cappelletti; P Costa; C Sellitto; L Cantoni; M Carelli; R Faggioni; G Fantuzzi; P Ghezzi; V Poli
Journal:  J Exp Med       Date:  1994-10-01       Impact factor: 14.307

9.  The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps.

Authors:  Sébastien Jaillon; Giuseppe Peri; Yves Delneste; Isabelle Frémaux; Andrea Doni; Federica Moalli; Cecilia Garlanda; Luigina Romani; Hugues Gascan; Silvia Bellocchio; Silvia Bozza; Marco A Cassatella; Pascale Jeannin; Alberto Mantovani
Journal:  J Exp Med       Date:  2007-03-26       Impact factor: 14.307

10.  The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages.

Authors:  Maria Ruweka Fernando; Jose Luis Reyes; Jordan Iannuzzi; Gabriella Leung; Derek Mark McKay
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

View more
  2 in total

1.  Impact of acute high-intensity interval exercise on plasma pentraxin 3 and endothelial function in obese individuals-a pilot study.

Authors:  Aaron L Slusher; Brandon G Fico; Katelyn M Dodge; Ryan S Garten; Peter J Ferrandi; Alexandra A Rodriguez; Gabriel Pena; Chun-Jung Huang
Journal:  Eur J Appl Physiol       Date:  2021-02-27       Impact factor: 3.078

2.  Aerobic Training Down-Regulates Pentraxin 3 and Pentraxin 3/Toll-Like Receptor 4 Ratio, Irrespective of Oxidative Stress Response, in Elderly Subjects.

Authors:  Brisamar Estébanez; Alexandra L Rodriguez; Nishant P Visavadiya; Michael Whitehurst; María J Cuevas; Javier González-Gallego; Chun-Jung Huang
Journal:  Antioxidants (Basel)       Date:  2020-01-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.